Skip to main content
. 2022 Dec 20;90(3):289–297. doi: 10.1007/s12098-022-04420-9

Table 5.

Empiric antimicrobial treatment in VAP

Scenario Empiric regimen
Most cases Cefepime or ceftazidime or meropenem
Sepsis or septic shock or necrotizing pneumonia Vancomycin plus cefepime or ceftazidime or meropenem
MRSA colonization or prior MRSA infection Vancomycin plus cefepime or ceftazidime or meropenem
Vancomycin-resistant cases Linezolid
Allergy to penicillin and cephalosporin Vancomycin plus aztreonam
Recent infection with MDR organism within 90 d ESBL producer: meropenem

VAP Ventilator-associated pneumonia